Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Alnylam Pharmaceuticals Stock Surges Despite 50% Volume Drop Ranking 455th in Market Activity

Market BriefWednesday, May 7, 2025 8:03 pm ET

1min read

On May 7, 2025, Alnylam Pharmaceuticals (ALNY) saw a trading volume of $211 million, a significant decrease of 50.29% from the previous day, ranking 455th in the day's stock market activity. The stock price of Alnylam Pharmaceuticals increased by 2.50%.

Alnylam Pharmaceuticals, Inc. (ALNY) has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for patisiran, an investigational RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).

The FDA has granted patisiran Breakthrough Therapy designation, which is intended to expedite the development and review of drugs for serious or life-threatening conditions. This designation is based on preliminary clinical evidence that indicates patisiran may demonstrate substantial improvement over existing therapies.

Alnylam's stock price has been influenced by the positive news regarding the FDA's acceptance of the NDA for patisiran. Investors are optimistic about the potential of patisiran to treat hATTR amyloidosis, a rare and debilitating disease. The Breakthrough Therapy designation further enhances the company's prospects, as it indicates that the FDA recognizes the potential of patisiran to address an unmet medical need.

In addition to the FDA's acceptance of the NDA, Alnylam has also reported positive results from its Phase 3 clinical trial of patisiran. The trial demonstrated that patisiran significantly reduced the levels of transthyretin protein in patients with hATTR amyloidosis, which is a key indicator of the drug's efficacy. These positive results have further bolstered investor confidence in Alnylam's pipeline and its potential to bring innovative therapies to market.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.